Full Issue

Individual Articles - Jan/Feb 2025 - Volume 29, Number 1

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jan/Feb 2025 Pg. 4	Prescription - Continuation, Compounding and Collaboration Author(s): Kupiec Thomas C
Jan/Feb 2025 Pg. 6-13	Navigating the Direct Importation of Active Pharmaceutical Ingredients: Compliance Considerations for Compounding Pharmacies Author(s): Byars Bradley S, Howard Brad
Jan/Feb 2025 Pg. 14-21	K-Carrageenan-Tapioca Starch-Based Vegetable Capsules: A Sustainable Gelatin Alternative-Compounding and Characterization Study Author(s): Kumaravelrajan Rajagopal, Arockiyasamy Kishore metha, Venkatesan Suba, Thiraviam Purushoth Prabhu
Jan/Feb 2025 Pg. 22-27	Best Practices When Compounding FDA-Approved Drugs Listed in Shortage Author(s): Alliance for Pharmacy Compounding
Jan/Feb 2025 Pg. 28-32	Best Practices for Marketing Compounded Medications Author(s): Alliance for Pharmacy Compounding
Jan/Feb 2025 Pg. 33-36	Compounded GLP-1 Drugs and Patient Adverse Events Author(s): Alliance for Pharmacy Compounding
Jan/Feb 2025 Pg. 38-39	Standard Operating Procedure: Calculating the Endotoxin Load in Compounded Sterile Preparations Author(s):
Jan/Feb 2025 Pg. 40	Calculations - Salicylic Acid Ointments - Percent Strength of a Semisolid Dosage Form, Alligation Alternate Method of Calculation, Temperature Conversion Author(s): Stockton Shelly J
Jan/Feb 2025 Pg. 42	Allopurinol 20-mg/mL Oral Suspension Author(s):
Jan/Feb 2025 Pg. 43-44	Chloral Hydrate 25-mg/mL Oral Suspension Author(s):
Jan/Feb 2025 Pg. 45	Ketoprofen 10% in Pluronic Lecithin Organogel Author(s):
Jan/Feb 2025 Pg. 46	Lansoprazole 3-mg/mL Oral Suspension Author(s):
Jan/Feb 2025 Pg. 47	Levothyroxine Sodium 40-ug/mL Oral Liquid Author(s):
Jan/Feb 2025 Pg. 48	Nifedipine 0.5% Rectal Ointment Author(s):
Jan/Feb 2025 Pg. 49	Rifaximin 20-mg/mL Oral Suspension Author(s):
Jan/Feb 2025 Pg. 50	Sertraline Hydrochloride 10-mg/mL Oral Suspension Author(s):
Jan/Feb 2025 Pg. 51	Three Fortified Ophthalmic Solutions: Amikacin 5% Ophthalmic Solution; Ceftazidime 5% Ophthalmic Solution; Vancomycin 5% Ophthalmic Solution Author(s):
Jan/Feb 2025 Pg. 52-63	Compounded Tirzepatide Therapy for Weight Loss: A Health Economics & Outcomes Research (HEOR) Analysis Author(s): Guth Michael AS
Jan/Feb 2025 Pg. 64-76	Compatibility of 17-a-estradiol, Caffeine, Clobetasol Propionate, Finasteride Melatonin, Metronidazole, Spironolactone, Tretinoin, and Triamcinolone in Trichosol, a Natural Vehicle for Hair Solutions Author(s): Kegele Carolina Schettino, Marianni Bruna, Polonini Hudson
Jan/Feb 2025 Pg. 77-84	Biopharmaceutical Performance of DiluCap: A Line of Functional Excipients Enhancing Dissolution Profiles of Minoxidil, Finasteride, Melatonin, and Naltrexone Author(s): Kegele Carolina Schettino, Ferreira Anderson de Oliveira, Koulouridas Savvas, Polonini Hudson